What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?

Abstract

Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-interval measurement), and hepatotoxicity (measurement of ASAT/ ALAT).

Keywords

• коронавирус
• комбинированная терапия
• гидроксихлорохин
• лопинавир/ритонавир
• covid-19
• кардиотоксичность
• гепатотоксичность